Medically reviewed by Eland Siddle, PharmD · Last updated July 2026
Newborn screening is one of the most successful public health programs in U.S. history. Within 24 to 48 hours of birth, a simple heel-prick blood spot combined with a hearing test and a pulse oximetry check gives hospitals and families early warning about dozens of serious but treatable conditions. For the conditions it catches, it works remarkably well.
But the program was never designed to be comprehensive. It is a triage tool, built around a specific public health model: identify a short list of conditions where early intervention meaningfully changes outcomes, then act fast. That design comes with real structural limits. Understanding those limits isn't a reason to worry; it's a reason to be informed.
This article walks through how newborn screening is structured, where the gaps are by design, and what options parents have if they want broader information about their child's genetic health.
How Newborn Screening Is Structured and Why It Varies by State
Newborn screening in the United States is state-run, not federal. Each state sets its own panel of conditions, which means the number of conditions screened varies considerably across the country, roughly 30 to 80 depending on where a baby is born.
The federal government publishes a Recommended Uniform Screening Panel (RUSP), which currently lists 37 core conditions and 26 secondary conditions. States use the RUSP as guidance, but they are not required to follow it. Some states screen for significantly more conditions than the RUSP recommends; others screen for fewer.
What This Means in Practice
A baby born in one state may be screened for a condition that a baby born in a neighboring state is not. This isn't a gap in care caused by error or neglect. It reflects deliberate policy choices at the state level, often shaped by evidence, cost, treatment availability, and lab infrastructure. But it does mean that a baby's birthplace influences the scope of their initial screening.
The table below illustrates the range of variation across a sample of states. (Exact panel sizes shift as states add conditions; check your state health department for the current panel.)
| State | Approximate Conditions Screened | Notes |
|---|---|---|
| California | ~80+ | One of the broadest panels in the country |
| New York | ~50+ | Includes several conditions beyond the RUSP core |
| Texas | ~50+ | Follows RUSP closely with periodic additions |
| Missouri | ~30+ | Smaller panel; aligns with RUSP core conditions |
The variation is real, but the more important point is structural: even the largest state panels screen a fraction of the 7,000+ known genetic conditions. Newborn screening was never meant to cover all of them.
It Happens Once, at a Single Point in Time
Newborn screening is a one-time test, typically performed within the first two days of life. That timing is intentional: the goal is to catch conditions early enough to intervene before symptoms appear.
The limitation is that a single snapshot at birth cannot capture everything relevant to a child's long-term health. Many genetic conditions are not present at detectable levels in the newborn period, or they manifest only later in childhood or adolescence. The program is not designed to track genetic health across a child's development. It screens for a defined set of conditions at a single moment.
Later-Onset Conditions
Some genetic conditions that affect children significantly (in areas like cardiac health, neurological development, connective tissue, or immune function) may not be flagged by a newborn screen because they are outside the program's scope or their markers are not reliably detectable at birth. This is a structural feature of the program, not a flaw in execution. For a closer look at which condition categories fall outside the standard panel, see our companion article on what newborn screening misses.
No Pharmacogenomic Component
Standard newborn screening provides no information about how a child's genetics may affect their response to medications. This area, pharmacogenomics, looks at genetic variants that influence drug metabolism, efficacy, and the risk of adverse reactions.
Pharmacogenomic information can be relevant throughout a child's life. For common medications like certain antibiotics, pain relievers, and psychiatric drugs, genetic variants can mean a standard dose is too little, too much, or potentially harmful. Newborn screening was not designed to address this, and currently no state panel includes pharmacogenomic markers.
For parents who want this layer of information proactively, before a child ever needs a prescription, it requires a separate test.
False Positives and False Negatives: What the Rates Mean
No screening test is perfect, and newborn screening is no exception. Two types of errors can occur:
- False positives: The screen flags a potential issue that follow-up testing does not confirm. These results require diagnostic workup and can cause significant parental anxiety before being resolved. False positives are a known feature of any population-level screening program, the tradeoff for catching true cases early.
- False negatives: A condition is present but not detected. This can happen due to the timing of the sample, the specific biochemical markers used, or the inherent sensitivity limits of the assay. It is uncommon but not impossible.
Neither of these reflects a broken system. They are inherent characteristics of screening at scale, and clinicians who work with newborn screening results account for them. What matters for parents is understanding that a normal newborn screen does not rule out all genetic conditions, only the specific conditions on the panel, with the sensitivity of the specific tests used.
What Parents Can Do
Knowing the structural limits of newborn screening does not require action for most families. For many children, the standard program is sufficient for the conditions it is designed to catch. But for parents who want more complete information, a few options are worth knowing about:
- Ask about your state's panel. Your state health department publishes its current newborn screening panel. Knowing what is and is not included helps you have a more informed conversation with your pediatrician.
- Talk to your pediatrician about family history. If there is a known genetic condition in the family, your pediatrician may recommend targeted diagnostic testing beyond what the standard screen covers.
- Consider expanded genetic screening. For families who want a broader picture of their child's genetic health, including conditions outside the state panel, later-onset conditions, and medication-related genetic variants, comprehensive pediatric genetic screening is available outside the newborn period.
Where Fore Fits
Fore's pediatric genetic health screen is designed as a complement to newborn screening, not a replacement for it. Where the state program screens a defined list of conditions at birth, Fore uses whole-genome sequencing (WGS), sequencing 100% of a child's DNA, to screen for 1,000+ genetic conditions and 100+ medication interactions. It's done at home with a cheek swab, with no clinic visit or referral required.
Because Fore stores each child's genome, results can be reanalyzed over time as genetic science advances, without collecting a new sample. Board-certified genetic counseling is included, so families don't interpret complex results alone.
For parents who have completed the standard newborn screen and want a more complete picture of their child's genetic health, learn more about what Fore screens for. You may also find it useful to read how the state newborn screen and Fore compare side by side.
For a deeper look at which specific conditions fall outside standard panels, see what standard newborn screening misses.
Personalized Care, Not Prediction
The limits of newborn screening aren't a reason to worry. They're a reason to think about what comes next.
Traditional medicine tends to ask one question: is my child sick? Fore is built around a different one: how do we help keep them healthy? That shift matters, because a genetic finding is not a diagnosis.
- A variant is not a verdict. Most children who carry one will never develop the associated condition.
- It points to personalized care, not a fixed fate. A finding identifies who may benefit from closer attention, not who is destined to get sick.
- It gives your pediatrician a head start. Depending on the finding, that can mean earlier eye or hearing exams, periodic heart monitoring, earlier cholesterol screening, avoiding a specific medication, or simply noting the result to watch over time.
- The goal isn't predicting the future. It's making your child's care more personalized from day one.
Fore's at-home whole genome screen covers 1,000+ conditions and 100+ medication responses, includes board-certified genetic counseling, and reanalyzes your child's genome over time as science advances. See what Fore screens for.
FAQs
Why does newborn screening vary by state?
Newborn screening is administered by each state individually, not by the federal government. States use federal guidance (the Recommended Uniform Screening Panel) but set their own panels based on evidence, budget, lab capacity, and available treatments. As a result, the number of conditions screened ranges from roughly 30 to 80 depending on where a baby is born.
Can newborn screening miss a genetic condition?
Yes. Newborn screening only tests for the specific conditions on a state's panel, using assays with defined sensitivity limits. Conditions outside the panel are not screened for. Even within the panel, a small number of false negatives can occur. A normal result means no evidence of the screened conditions. It does not rule out all genetic conditions.
Does newborn screening test for medication reactions?
No. Standard newborn screening does not include pharmacogenomic testing. It does not assess genetic variants that affect how a child responds to medications. That information requires a separate test and is not part of any current state newborn screening program.
My baby's newborn screen came back with an abnormal result. Does that mean something is wrong?
Not necessarily. Abnormal or out-of-range results on a newborn screen often turn out to be false positives, results that do not hold up under follow-up diagnostic testing. An abnormal screen is a prompt to investigate further, not a diagnosis. Your pediatrician will guide next steps, which typically involve confirmatory testing and, if warranted, referral to a specialist or genetic counselor.
Is there a way to get more comprehensive genetic screening for my child after the newborn period?
Yes. Comprehensive pediatric genetic health screens using technologies like whole-genome sequencing are available outside the newborn period and can cover a much broader range of conditions and medication interactions than the standard state panel. These are voluntary and not covered by the public health program. Talking with your pediatrician or a genetic counselor can help you decide whether expanded screening makes sense for your family.